
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Since the mid-1980s, mounting evidence has shown that psoriasis is an immune disorder - specifically, that abnormal T-cell activity is a critical component of the disease.






